Prof Greg Hannon elected Fellow of the AACR Academy Class of 2020
Institute Director Prof Greg Hannon has joined 19 leading cancer researchers to be elected Fellows of the American Association for Cancer Research (AACR) Academy.
The mission of the AACR Academy is to recognise and honour distinguished scientists whose scientific contributions have propelled significant innovation and progress against cancer. Fellows of the AACR Academy serve as a global brain trust in the cancer field, helping to advance the mission of the AACR to prevent and cure all cancers through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.
Professor Greg Hannon has been recognised for fundamental contributions to characterizing the role of cyclin-dependent kinases and small RNAs including microRNAs, piwi-interacting, and short-hairpin RNAs in cell cycle regulation, carcinogenesis, and drug development.
All Fellows are nominated and elected through an annual peer review process conducted by existing Fellows of the AACR Academy and ratified by the AACR Academy Steering Committee and AACR Executive Committee. This process involves a rigorous assessment of each candidate’s scientific accomplishments in cancer research and cancer-related sciences. Only individuals whose work has had a significant and enduring impact on cancer research are considered for election and induction into the AACR Academy.
“This year’s collection of elected Fellows of the AACR Academy continues the AACR’s rich tradition of recognizing the most significant contributors to cancer research,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “The 2020 class consists of 19 trailblazing pioneers in various scientific areas who have accelerated the pace of progress against cancer. We are honored to have them join our 212 existing Fellows and look forward to celebrating their scientific accomplishments.”
Related News
See all news-
New immune pathway offers treatment hope for childhood brain tumours
3rd February 2026
A newly discovered immune pathway could lead to gentler treatments for multiple childhood brain cancers, according to new research from our Gilbertson Group published today in Nature Genetics.
Find out more -
Targeting paused cells could improve chemotherapy for lung and ovarian cancers
3rd February 2026
New research published today in Nature Aging by scientists at the University of Cambridge sheds light on why some lung and ovarian cancers stop responding to chemotherapy, and how this resistance might one day be prevented.
Find out more -
Hot flush treatment has anti-breast cancer activity, study finds
5th January 2026
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a new Cambridge-led trial has found.
Find out more